EGF receptor family: Twisting targets for improved cancer therapies

Antony W. Burgess, Yoav I. Henis, Nancy E. Hynes, Thomas Jovin, Alexander Levitzki, Ronit Pinkas-Kramarski, Yosef Yarden

Research output: Contribution to journalArticlepeer-review


The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalGrowth Factors
Issue number2
StatePublished - Apr 2014


  • Cell surface
  • ErbB2
  • ErbB3
  • FLIM
  • FRET
  • Receptor dynamics
  • Therapeutic antibodies

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'EGF receptor family: Twisting targets for improved cancer therapies'. Together they form a unique fingerprint.

Cite this